U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo1
CheckMate -76K marks the fifth Opdivo-based indication in earlier stages of cancer, in the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA) | Melanoma | Skin Cancer | Statistics